Blog Menu

Male Pattern Baldness Linked to Increased Prostate Cancer Risk

Male pattern baldness has long been a source of anxiety for men, raising concerns of appearance and aging. Aside from aesthetic effects, though, it can have much more serious implications. An early September study on the relationship between male pattern baldness and prostate cancer indicated that there was a definite connection between the two.

Specifically, men over 45 with vertex pattern balding are at 39 percent higher risk for aggressive prostate cancer. The connecting factor between hair loss and prostate cancer is male hormones, also know as androgens. The androgens testosterone and dihydrotestosterone (DHT) are associated both with balding and with prostate development and cancer. These are most likely the link between the two conditions.

Interestingly, DHT suppression is a main function in the hair loss drug Propecia.

Using Propecia for Hair Loss: Persistent Sexual Side Effects

Although DHT suppression shows success in fighting hair loss, it also contributes to the sexual side effects of Propecia. Propecia’s active ingredient of finasteride is responsible for blocking this hormone as well as for the side effects.
Propecia side effects include:

  • Erectile Dysfunction
  • Loss of Libido
  • Ejaculatory Disorder
  • Genital Soreness/Pain

Unfortunately, some of these side effects, such as erectile problems and reduced libido, can persist long after ceasing to take Propecia.… Read the rest


Pharmaceutical News Wrap Up: October 2014

The Simmons Hanly Conroy pharmaceutical lawyers are dedicated to providing you with the latest pharmaceutical news. Below is a short list of some of the most recent headlines concerning FDA recalls and warning label changes, medical studies and other pharmaceutical news taking place across the globe .

  • Antidote for anticoagulant Pradaxa to be tested in Hamilton
    Read pharmaceutical news from Simmons Hanly ConroyFive Canadian hospitals are participating in a clinical trial that tests an antidote for Pradaxa, a blood-thinning medication that has been linked to serious bleeding. The drug’s manufacturer, Boehringer Igelheim, hopes the antidote will be able to reverse the serious effects of Pradaxa’s anticlotting abilities.

 … Read the rest


Blood Thinner Xarelto Linked to Life-Threatening Side Effects

This year, claims have been filed by patients and their family members who say the use of blood thinner Xarelto has led to serious, irreversible internal bleeding and death. The drug currently has no antidote for internal bleeding side effects, and claimants argue that the drug’s manufacturer, Johnson & Johnson, did not publicize such risks.

Xarelto side effectsIn November 2012, the U.S. Food and Drug Administration (FDA) approved Xarelto (rivaroxaban), a blood thinner used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Initially, Xarelto was the first and only oral anticoagulant approved to treat DVT and PE without the need for injections or routine blood monitoring.

Contrary to the belief that the blood thinner Xarelto would help prevent life-threatening conditions like stroke and heart problems, many individuals are now facing health issues that are just as debilitating – if not more debilitating – than the diseases they were trying to prevent.

Specifically, the blood-thinner has been associated with:

  • Rectal bleeding
  • Intestinal bleeding
  • Abdominal bleeding
  • Hemorrhaging in the brain

If you are taking Xarelto, talk to your doctor about your risk for any of the above life-threatening side effects. Do not stop taking any medication before seeking advice from a physician. If you have experienced any of the above side effects, see a doctor immediately.… Read the rest


6 Lipitor Side Effects You May Not Be Aware Of

Like many pharmaceutical drugs, Lipitor can cause problems as serious as those it is solving. Lipitor is prescribed to lower ‘bad’ (LDL) cholesterol and triglycerides as well as to raise ‘good’ (HDL) cholesterol. It is also supposed to lowerthe risk of heart attack, stroke, and chest pain. But, Lipitor lawsuits have risen as a result of the drug’s link to type 2 diabetes, which has been validated by numerous studies.

Lipitor side effectsThe drug was approved by the Food and Drug Administration (FDA) in 1996 and is distributed by Pfizer, an American pharmaceutical company. It is also known by its generic name atorvastatin.

Lipitor is a statin, a class of drugs used to lower lipids and prevent the liver from producing cholesterol. But, statins are also linked to elevated blood sugar levels. Lipitor side effects can range from irritating to life-threatening and they are not always made clear to those using the drug.

Some of the more severe yet lesser known side effects of Lipitor include:

  • Memory loss
  • Muscle problems
  • Liver problems
  • Jaundice
  • Kidney failure
  • Type 2 diabetes

These Lipitor adverse reactions can be alarming as well dangerous. Seek a doctor immediately if you are experiencing any of these symptoms.

If you believe that you or a loved one has been negatively affected by Lipitor, contact the Lipitor lawyers at Simmons Hanly Conroy.… Read the rest


Pradaxa Manufacturer Pays $650 Million in a Comprehensive Settlement

Earlier this year, Boehringer Ingelheim, the manufacturer of Pradaxa (dabigatran), agreed to pay $650 million in a comprehensive settlement related to lawsuits issued by users of the drug. Reports of death, bleeding and stroke among individuals taking the blood-thinning medication have been ongoing since its introduction to the market in October, 2010.

FDANumerous studies have focused on the link between Pradaxa and serious side effects. In December 2011, U.S. regulators issued a safety announcement regarding the post-market reports of serious bleeding events among Pradaxa users. More than 260 fatal bleeding incidents have been confirmed by Boehringer Ingelheim.

The comprehensive settlement decision comes from the knowledge that the blood thinner manufacturer may have failed in its duty to adequately warn consumers about the frequency of bleeding events compared to traditional anticoagulants. Warfin, the long-standing blood-thinning medication has a reversal agent or antidote for dangerous side effects, while Pradaxa does not.

The settlement agreement comes less than a year after Boehringer Ingelheim filed for additional marketing approvals for Pradaxa, according to the NY Tmes. The additional marketing would present the drug as a treatment for deep vein thrombosis and pulmonary embolism.

Simmons Hanly Conly Pradaxa lawyers are no longer accepting clients in this area.… Read the rest

168 queries. 0.820 seconds